GlassScriptPhysician profile
Trey T Young
NPI 1942735618
$2,474.11
in general payments reported to CMS, 2019-2025
27 companies · $901 in 2025
The $901 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $14.01 · 2022: $192 · 2023: $155 · 2024: $1,211 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,267.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $474.18 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Supernus Pharmaceuticals, INC. | $276.73 | 2024 | Qelbree |
| Pfizer INC. | $267.97 | 2022-2025 | |
| Lilly USA, LLC | $224.33 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $148.89 | 2024-2025 | |
| Novo Nordisk INC | $129.02 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $114.11 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $113.30 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lucid Diagnostics INC. | $91.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.55 | 2023-2025 | Trintellix |
| Astellas Pharma US INC | $83.50 | 2023-2025 | Veozah |
| Abbott Laboratories | $78.21 | 2023-2025 | Freestyle Libre 3 |
| Amgen INC. | $71.00 | 2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.99 | 2024-2025 | Xifaxan |
| Antares Pharma, INC. | $33.28 | 2024-2025 | Xyosted |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $32.51 | 2024 | Doc Band |
| Tolmar, INC. | $27.70 | 2025 | Jatenzo |
| Acadia Pharmaceuticals INC | $26.90 | 2024 | Daybue |
| Biogen, INC. | $24.43 | 2024 | Skyclarys |
| Sumitomo Pharma America, INC. | $20.43 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $16.88 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $16.32 | 2024 | Nuzyra |
| Sanofi-Aventis U.S. LLC | $15.48 | 2025 | |
| Galderma Laboratories, L.P. | $15.36 | 2024 | |
| Glaxosmithkline, LLC. | $15.02 | 2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.19 | 2023 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $14.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trey Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.